Trials / Withdrawn
WithdrawnNCT05609812
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Vera Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.
Detailed description
The study will assess atacicept vs. placebo on the impact of renal function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atacicept | Once weekly subcutaneous (SC) injections by prefilled syringe |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2022-11-02
- Primary completion
- 2026-03-15
- Completion
- 2028-12-15
- First posted
- 2022-11-08
- Last updated
- 2025-05-23
Locations
33 sites across 3 countries: United States, Puerto Rico, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05609812. Inclusion in this directory is not an endorsement.